NASDAQ:NVLN Novelion Therapeutics (NVLN) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free NVLN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.68▼$0.7052-Week Range N/AVolume26,947 shsAverage Volume190,529 shsMarket Capitalization$13.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Novelion Therapeutics alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Novelion Therapeutics Stock (NASDAQ:NVLN)Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> NVLN Stock News HeadlinesJune 2, 2023 | finance.yahoo.comCYTO - Altamira Therapeutics Ltd.See More Headlines Receive NVLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novelion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2019Today4/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NVLN CUSIPN/A CIK827809 Webwww.novelion.com Phone617-500-7867FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,330,000.00 Net Margins-79.43% Pretax MarginN/A Return on EquityN/A Return on Assets-26.13% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.21 Sales & Book Value Annual Sales$130.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($4.69) per share Price / BookN/AMiscellaneous Outstanding Shares19,619,000Free FloatN/AMarket Cap$13.77 million OptionableOptionable Beta2.12 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Benjamin S. Harshbarger (Age 50)Interim CEO, Gen. Counsel & Corp. Sec. Mr. Michael D. Price (Age 61)Exec. VP & CFO Mr. Roger W. Louis (Age 63)Global Chief Compliance Officer and Head of R&D Ms. Barbara Y. Chan (Age 55)VP & Chief Accounting Officer Ms. Amanda MurphyDirector of Investor Relations & Corp. CommunicationsKey CompetitorsTraws PharmaNASDAQ:TRAWNanoViricidesNYSE:NNVCAvalo TherapeuticsNASDAQ:AVTXABVC BioPharmaNASDAQ:ABVCTonix PharmaceuticalsNASDAQ:TNXPView All Competitors NVLN Stock Analysis - Frequently Asked Questions How were Novelion Therapeutics' earnings last quarter? Novelion Therapeutics Inc. (NASDAQ:NVLN) posted its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $0.13. The biotechnology company had revenue of $40.71 million for the quarter, compared to the consensus estimate of $40.90 million. What other stocks do shareholders of Novelion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novelion Therapeutics investors own include Aralez Pharmaceuticals (ARLZ), Amicus Therapeutics (FOLD), Applied Genetic Technologies (AGTC), Advanced Micro Devices (AMD), Biocept (BIOC), Karyopharm Therapeutics (KPTI), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and Actinium Pharmaceuticals (ATNM). This page (NASDAQ:NVLN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThey say it’s ‘unstoppable’ – How I made 43,509% Investing Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novelion Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.